Pinealon (10mg)

    Short peptide — neuroprotection & cognitive ageing

    650.000 ₫

    Delivery method:

    Single vial

    650.000 ₫

    Pinealon pen (10mg)

    845.000 ₫

    Needs cold shipping

    Pinealon is a short tripeptide (Glu-Asp-Arg) developed in the Khavinson Russian gerontology programme. It is one of the very few peptides small enough to cross the blood-brain barrier intact, and is researched for neuroprotection, cognitive ageing endpoints and cellular longevity at the level of the CNS. Researched outcomes include protection of cortical neurons from oxidative stress, improvement in cognitive function in ageing models, normalisation of pineal–circadian signalling, and support for the glymphatic clearance work the brain performs during deep sleep. Often positioned alongside Epithalon as a neuro-longevity tool. Typically run in short evening cycles. 10mg vial.

    Dosage

    Typical research dose: 1-5 mg subcutaneously, daily for 10-20 days, repeated in cycles.

    Duration of effect

    Course-based; neuro benefits persist for weeks after (plasma half-life: Short plasma half-life)

    See full half-life table →

    Key Features

    • Short peptide — BBB penetrant
    • Neuroprotection research
    • Cyclical dosing protocol
    • 10mg vial
    Contact Us

    Includes key details, half-life data, usage notes and research sources.

    Usage Instructions

    Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.

    Research Highlights

    • Backed by scientific research
    • Manufactured to pharmaceutical standards
    • Used in clinical research settings
    • Established safety profile

    Safety Information

    • •Consult your healthcare provider before use
    • •Not intended for pregnant or nursing women
    • •Store properly according to instructions
    • •Report any adverse effects to your healthcare provider

    Source: Khavinson et al., Int. J. Mol. Sci. (PMC, 2022)

    Clinical Research

    The ultrashort tripeptide Pinealon (EDR) penetrates the blood-brain barrier and modulates neuroepigenetic mechanisms relevant to Alzheimer's disease — reducing oxidative neuronal damage and supporting expression of genes involved in synaptic maintenance in published preclinical work.

    Read full study

    Additional Research

    Source: Khavinson et al., Pharmaceuticals (PMC, 2022)

    Transport studies confirm Pinealon and related ultrashort peptides cross epithelial barriers intact via POT and LAT carriers — establishing the route by which orally or systemically administered peptide reaches the CNS to exert neuroprotective effects.

    Read full study